EF Stange

596 total citations
34 papers, 368 citations indexed

About

EF Stange is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, EF Stange has authored 34 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 13 papers in Genetics and 10 papers in Surgery. Recurrent topics in EF Stange's work include Inflammatory Bowel Disease (13 papers), Drug Transport and Resistance Mechanisms (6 papers) and Autoimmune and Inflammatory Disorders (4 papers). EF Stange is often cited by papers focused on Inflammatory Bowel Disease (13 papers), Drug Transport and Resistance Mechanisms (6 papers) and Autoimmune and Inflammatory Disorders (4 papers). EF Stange collaborates with scholars based in Germany, Switzerland and Sweden. EF Stange's co-authors include Klaus Fellermann, K Herrlinger, Matthias Schwab, Klaus Herrlinger, D Ludwig, G. Wiedemann, H. Koop, Eike Burmester, Michael Fuchs and Maria Schindler and has published in prestigious journals such as Gastroenterology, Gut and Journal of Lipid Research.

In The Last Decade

EF Stange

31 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
EF Stange Germany 12 148 134 131 94 44 34 368
J. Boix Spain 8 132 0.9× 135 1.0× 122 0.9× 63 0.7× 32 0.7× 25 345
Stefano Festa Italy 9 122 0.8× 102 0.8× 160 1.2× 89 0.9× 26 0.6× 29 362
Eileen W. Tsai United States 14 143 1.0× 126 0.9× 51 0.4× 144 1.5× 69 1.6× 16 647
Riko Ichikawa Japan 7 155 1.0× 88 0.7× 97 0.7× 205 2.2× 13 0.3× 7 434
Walter H. Jacobs United States 6 122 0.8× 173 1.3× 209 1.6× 40 0.4× 38 0.9× 11 411
Angela Variola Italy 10 142 1.0× 80 0.6× 152 1.2× 115 1.2× 39 0.9× 32 355
Daisuke Takei Japan 12 263 1.8× 231 1.7× 196 1.5× 124 1.3× 20 0.5× 44 486
Irena Brabcová Czechia 13 145 1.0× 33 0.2× 64 0.5× 77 0.8× 33 0.8× 20 434
Piotr Radwan Poland 10 65 0.4× 116 0.9× 88 0.7× 116 1.2× 16 0.4× 32 471
Mircea Mănuc Romania 12 110 0.7× 106 0.8× 170 1.3× 52 0.6× 18 0.4× 53 443

Countries citing papers authored by EF Stange

Since Specialization
Citations

This map shows the geographic impact of EF Stange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EF Stange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EF Stange more than expected).

Fields of papers citing papers by EF Stange

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EF Stange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EF Stange. The network helps show where EF Stange may publish in the future.

Co-authorship network of co-authors of EF Stange

This figure shows the co-authorship network connecting the top 25 collaborators of EF Stange. A scholar is included among the top collaborators of EF Stange based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EF Stange. EF Stange is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dignaß, Axel, Daniel C. Baumgart, Hendrik Lehnert, et al.. (2015). Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. Journal of Crohn s and Colitis. 10(1). 31–37. 13 indexed citations
2.
Herrlinger, K, Stefan Winter, Alexander Teml, et al.. (2011). ABCB1 Single-Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis. Clinical Pharmacology & Therapeutics. 89(3). 422–428. 39 indexed citations
3.
Escher, Monica, EF Stange, & Klaus Herrlinger. (2010). Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis — A need for prophylaxis. Journal of Crohn s and Colitis. 4(5). 606–609. 18 indexed citations
4.
Herrlinger, Klaus, et al.. (2010). Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Alimentary Pharmacology & Therapeutics. 31(9). 1036–1041. 38 indexed citations
5.
Herrlinger, K & EF Stange. (2010). Therapie des Morbus Crohn: Step-up oder Top-down?. DMW - Deutsche Medizinische Wochenschrift. 135(34/35). 1694–1698. 1 indexed citations
6.
Schreyer, A., S. Koletzko, Jedrzej Hoffmann, et al.. (2009). Aktualisierte S 3-Leitlinie zur Diagnostik des Morbus Crohn – radiologische Untersuchungstechniken. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 182(2). 116–121. 12 indexed citations
7.
Rothfuss, Katja, J. Christian Bode, EF Stange, & Alexandr Parlesak. (2006). Urinary Excretion of Polyethylene Glycol 3350 during Colonoscopy Preparation. Zeitschrift für Gastroenterologie. 44(2). 167–172. 7 indexed citations
8.
Schmid, M, et al.. (2004). Defekte Induktion der Antiproteinasen Elafin und SLPI in entzündeter Colonschleimhaut beim Morbus Crohn. Zeitschrift für Gastroenterologie. 42(8). 1 indexed citations
9.
Stange, EF, Stefan Schreiber, Ulrich R. Fölsch, et al.. (2003). Diagnostik und Therapie des M. Crohn. Zeitschrift für Gastroenterologie. 41(1). 19–20.
10.
Schwab, Matthias, K Herrlinger, Elke Schaeffeler, & EF Stange. (2003). Therapie chronisch entzündlicher Darmerkrankungen mit Azathioprin, 6-Mercaptopurin und 6-Thioguanin. DMW - Deutsche Medizinische Wochenschrift. 128(8). 378–385.
11.
Herrlinger, K, Peter Deibert, Matthias Schwab, et al.. (2003). Remission maintenance by tioguanine in chronic active Crohn's disease. Alimentary Pharmacology & Therapeutics. 17(12). 1459–1464. 37 indexed citations
12.
Fricke, Lutz, et al.. (2001). Primary Hyperoxaluria Type 1 Causing End-Stage Renal Disease in a 45-Year-Old Patient. ˜The œNephron journals/Nephron journals. 87(1). 80–84. 1 indexed citations
13.
Habermann, Jens K., Claes Lenander, Uwe J. Roblick, et al.. (2001). Ulcerative Colitis and Colorectal Carcinoma: DNA-Profile, Laminin-5 γ2 Chain and Cyclin A Expression as Early Markers for Risk Assessment. Scandinavian Journal of Gastroenterology. 36(7). 751–758. 32 indexed citations
14.
Schimmelpenning, H., Jens K. Habermann, Stefan Krüger, et al.. (2000). Das Colitis ulcerosa-assoziierte kolorektale Karzinom - DNS-Ploidie als Indikator einer drohenden malignen Transformation? -. Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie. 125(Heft 11). 880–887. 1 indexed citations
15.
Koop, Irmtraut, et al.. (1996). Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids.. Gut. 39(5). 661–667. 42 indexed citations
16.
Schnabel, A., Klaus Dalhoff, EF Stange, Ulrich Mrowietz, & W L Gross. (1995). [Methotrexate therapy of inflammatory diseases. Reliable effects and recent developments in rheumatology, pneumology, gastroenterology and dermatology].. PubMed. 90(6). 364–71. 3 indexed citations
17.
Fuchs, Michael, et al.. (1994). Biliary cholesterol secretion and bile acid formation in the hamster: the role of newly synthesized cholesterol.. Journal of Lipid Research. 35(4). 690–697. 23 indexed citations
18.
Maucher, Helmut, et al.. (1990). Size exclusion chromatography for extraction of serum bile acids.. Journal of Lipid Research. 31(8). 1517–1522. 4 indexed citations
19.
Stange, EF, et al.. (1981). Treatment of ulcerative colitis.. BMJ. 282(6272). 1255–1256. 11 indexed citations
20.
Agostini, Bruno, et al.. (1974). [Proceedings: Diet-induced lipoprotein changes and their possible significance in atherogenesis in rabbits].. PubMed. 58. 555–555. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Boix Breakdown of academic impact, for papers by Stefano Festa Breakdown of academic impact, for papers by Eileen W. Tsai Breakdown of academic impact, for papers by Riko Ichikawa Breakdown of academic impact, for papers by Walter H. Jacobs Breakdown of academic impact, for papers by Angela Variola Breakdown of academic impact, for papers by Daisuke Takei Breakdown of academic impact, for papers by Irena Brabcová Breakdown of academic impact, for papers by Piotr Radwan Breakdown of academic impact, for papers by Mircea Mănuc
Rankless by CCL
2026